Agoracom Blog Home

Posts Tagged ‘small cap’

« Older Entries
Newer Entries »

VIDEO – Hollister $HOLL.ca Reports Record Q2 Revenues With $8.47M From 300+ Dispensaries In California and Arizona $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 6:28 PM on Tuesday, September 1st, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1

Hollister Biosciences (HOLL:CSE). is a multi-state operator with multiple, high-quality products that are now carried in 230 of California’s 600 dispensaries, where it also claims California’s #1 hash infused pre-roll “HashBone” + another 80 Arizona dispensaries with some of the best concentrate in the State.  

But given the state of disappointment in the Cannabis industry over the last 15 months, none of that would mean anything without actual results shareholders and the industry could celebrate.  In that regard, Hollister does not disappoint with Q2 numbers coming in as follows:

  • RECORD REVENUE of $US 8.47M, compared to $200,000 last year and representing an increase of 4,170%
  • NET INCOME of $300,000, compared to a loss of $2.1M, representing a turnaround of $2.4M over last year 

There isn’t a small cap cannabis company that would not cheer for these results – if that was all they had.  These numbers are a company maker.   But Hollister is set to continue growing on several fronts, including a Direct To Consumer model and further big expansion in California.  

Watch this incredible interview with President Alex Somjen.   

Watch this interview or listen by Podcast on Apple, Google, Spotify or your favourite podcaster.

Tags: , , , , , , , , , , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Featured, Hollister Biosciences | Comments Off on VIDEO – Hollister $HOLL.ca Reports Record Q2 Revenues With $8.47M From 300+ Dispensaries In California and Arizona $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

PyroGenesis $PYR.ca Announces Completion and Acceptance of Modelling Contract with Iron Ore Pelletization Client A; Receives Draft Contract for Equipment Purchase $RTN $NOC $UTX $DDD.ca $SSYS $PRLB

Posted by AGORACOM-JC at 3:13 PM on Tuesday, September 1st, 2020
  • Announced the completion and acceptance of its modeling contract with Client A which confirmed, amongst other things, that replacing fossil fuel burners with PyroGenesis’ proprietary plasma torches addresses the Client’s greenhouse gas reduction strategy/policy
  • PyroGenesis is also pleased to confirm receipt of a draft equipment purchase contract from Client A
  • Client’s name shall remain anonymous for competitive and confidential reasons

MONTREAL, Sept. 01, 2020 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch systems, further to its press release dated July 2nd, 2020, is pleased to announce the completion and acceptance of its modeling contract with Client A (the “Client”) which confirmed, amongst other things, that replacing fossil fuel burners with PyroGenesis’ proprietary plasma torches addresses the Client’s greenhouse gas reduction strategy/policy. PyroGenesis is also pleased to confirm receipt of a draft equipment purchase contract (the “Contract”) from Client A. The Client’s name shall remain anonymous for competitive and confidential reasons.

The modeling contract, disclosed in previous press releases, successfully demonstrated the benefits of replacing fossil fuel burners with PyroGenesis’ proprietary plasma torches. More specifically, two of the most important benefits demonstrated were i) that replacing fossil fuel burners with plasma torches was a simple replacement, plug and play process, and ii) that PyroGenesis’ proprietary plasma torches significantly reduce greenhouse gas emissions which, as a result, could play a significant role in Client A’s greenhouse gas reduction strategy/policy.

The Company also confirms having received a Contract which essentially highlights the terms and conditions negotiated to date. Although the major terms and conditions contained therein have been agreed to in principle, there are still several elements that need further review.

“The fact that we have received this Contract, on the heels of a successful modelling contract, from a significant player in the industry, clearly demonstrates the impact that PyroGenesis’ proprietary plasma torches are having in iron ore pelletization greenhouse gas reduction strategies,” said Mr. Peter Pascali, CEO and President of PyroGenesis. “Of note, PyroGenesis has the patent with respect to using plasma torches in iron ore pelletization as described. I must caution that although all parties are confident of the outcome, and the remaining details are minor, there is no guarantee that the Contract will, at the end of the day, be signed, until it is. We have no definite visibility on how long this will take but we are clearly in the final stages. We are all very excited at the significant role PyroGenesis’ proprietary plasma torches could play in reducing greenhouse gases, economically, all to the benefit of our planet.”

Pelletization is the process in which iron ore is concentrated before shipment, thus significantly reducing the cost of transportation. In conventional technologies, the process heat is provided by fuel oil or natural gas burners (both environmentally damaging). The combustion, in the burners, of fossil fuels results in the production of greenhouse gases, mainly CO2. Plasma torches, by contrast, utilize renewable electricity and as such offer an environmentally attractive alternative to fossil fuel burners.

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.

For further information please contact:
Rodayna Kafal, Vice President Investors Relations and Strategic Business Development
Phone: (514) 937-0002, E-mail: [email protected]

Tags: , , , , , , , ,
Posted in PyroGenesis Canada Inc. | Comments Off on PyroGenesis $PYR.ca Announces Completion and Acceptance of Modelling Contract with Iron Ore Pelletization Client A; Receives Draft Contract for Equipment Purchase $RTN $NOC $UTX $DDD.ca $SSYS $PRLB

Empower Clinics $CBDT.ca Announces Acquisition of Medical Diagnostics Laboratory $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:06 AM on Tuesday, September 1st, 2020

Empower intends to acquire Kai Medical Laboratory, a state-of-the-art diagnostics laboratory located in the medical district of Dallas, TX to advance COVID-19 national testing programs

  • Entered into a non-binding term sheet to acquire the business of Kai Medical Laboratory, LLC, by way of a share or asset acquisition, subject to due diligence and customary closing conditions
  • Kai Medical Laboratory is a high-complexity CLIA and COLA accredited Laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups
  • Kai Medical Laboratory offers a wide array of testing services ranging from hematology to hormone testing, endocrinology, toxicology, and immunology

VANCOUVER, BC / September 1, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (Frankfurt:8EC) (OTCQB:EPWCF) (“Empower” or the “Company“) today announces it has entered into a non-binding term sheet to acquire the business of Kai Medical Laboratory, LLC (“Kai Medical Laboratory“), by way of a share or asset acquisition, subject to due diligence and customary closing conditions.

Kai Medical Laboratory is a high-complexity CLIA and COLA accredited Laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. Kai Medical Laboratory offers a wide array of testing services ranging from hematology to hormone testing, endocrinology, toxicology, and immunology. These tests are done under the supervision of its well-qualified and highly experienced scientists, medical professionals, and pharmacists. https://www.kaimedicallaboratory.com

Kai Medical Laboratory has taken an active role in COVID-19 testing, battling the pandemic through RT-PCR testing and serology testing. While the RT-PCR test identifies if a patient has an active virus, the serology or antibody test detects if a patient has previously been exposed to the virus. Both of these test results are vital to managing outbreaks and the potential spread of coronavirus.

To further assist with COVID-19 testing, Kai Medical Laboratory has also developed two key programs in Texas and Arizona. The first program is a direct-to-consumer program that leverages the ability of various healthcare providers to order and administer both the RT-PCR test and the Antibody test. This increases the ability of the general population to be tested, in certain circumstances. The second is an Employer COVID-19 Compliance Program (ECCP) for business owners and employer groups to enable them to test and monitor their employees.

Texas program https://www.testtexasnow.com

Arizona program https://www.covidtest2u.com

Currently the lab has the capacity to complete in excess of 2,000 RT-PCR tests in one eight-hour shift by utilizing its Thermo Fisher QuantStudio 12k Flex testing machine. The lab also utilizes a Roche Cobas 6000 for COVID-19 Antibody testing, ensuring that Kai Medical Laboratory has the capability and capacity to serve a broad range of clients and test methods.

“Adding Kai Medical Laboratory to the Empower Clinics family enables us to dramatically expand COVID-19 testing capability and deliver phase four of our national rollout plan” said Steven McAuley, Empower’s Chairman & CEO. “Kai Medical has a newly built high-complexity lab offering a wide array of testing services, that together we will leverage to serve the massive demand for national COVID testing in the U.S. Further, as flu season arrives and a potential second-wave of COVID takes hold, the technical infrastructure of Kai Medical allows Empower to capture testing demand and the additional growth revenues associated with it.”

The driving force behind Kai Medical Laboratory’s remarkable growth and success is Yoshi Tyler. Yoshi has a passion for being an entrepreneur, and overtime, she found her true calling in healthcare. Driven by this interest, she pursued her career in the healthcare industry for more than two decades. She helmed leadership positions at a Fortune 500 pharmaceutical company for over thirteen years. These leadership experiences provided her with in-depth knowledge and industry insights that helped her to lead Kai Medical Laboratory towards growth.

The Kai Medical Laboratory team includes key roles including Principal Scientist, Director of Operations, Molecular Scientist, Quality Assurance, Lab Director and other critical roles.

“Kai Medical Laboratory is inspired by science and built on integrity. Our mission is to change healthcare through science & innovative quality care by providing value-added services, accuracy, and consistency. Our unwavering commitment to quality compliance and scientific innovation elevates Kai Medical Laboratory to a new standard in healthcare,” says Yoshi Tyler, the owner, and CEO of the company.

The proposed acquisition includes an 8,000 sq. ft. medical laboratory including covered drive up testing center, with premium testing and laboratory equipment, cash and current assets with a value in excess of $1,750,000.00 USD and a corporate office, both located in the heart of the medical district in Dallas, TX. Under the proposed terms Empower will assume a $1,200,000.00 USD Small Business Administration (SBA) equipment loan, a $150,000.00 SBA Economic Injury Disaster Loan and short-term liabilities of up to $250,000.00 at closing. In addition, Empower will issue 1,000,000 Company stock options to the Vendors, subject to the terms and conditions as set out in the Company Stock Option Plan.

Market Leading Technology Kai Medical Laboratory utilizes state-of-the-art instrumentation, preeminent testing methodologies, and laboratory services enabling high-complexity accredited laboratory testing solutions, providing some of the following key instrument testing capabilities:

  • Thermo Fisher – QuantStudio 12K Flex
    • COVID-19 testing
    • Cannabis Testing
    • Clinical Genomics
  • Roche Cobas 6000
    • COVID-19 Antibody testing
    • Clinical Chemistry/Endocrinology
  • AB SCIEX 6500+ – Liquid Chromatography Mass Spectrometry
    • Clinical Chemistry/Endocrinology
    • Agriculture/Cannabis testing
  • AB SCIEX 4500 – Liquid Chromatography Mass Spectrometry
    • Urine Toxicology
    • Cannabis testing
  • SYSMEX XN-550
    • Hematology

USA COVID-19 Data as at August 31, 2020

TOTAL CASES: 5,972,356

TOTAL DEATHS: 182,622

CASES IN LAST 7 DAYS: 289,865

ARIZONA as at August 31, 2020

CONFIRMED CASES: 199,984

PROBABLE CASES: 1,713

TOTAL CASES: 201,661

CASES IN LAST 7 DAYS: 3,558

CASES/100K: 1,769

DEATHS/100K: 70

TEXAS as at August 31, 2020

TOTAL CASES: 610,354

CASES IN LAST 7 DAYS: 32,817

CASES/100K: 2,126

DEATHS/100K: 46

(CLIA) The Clinical Laboratory Improvement Amendments regulate laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing.

(COLA) is the premier clinical laboratory accreditation, education and consultation organization. An independent accreditor whose practical, educational standards have a positive and immediate impact on patient care. http://www.cola.org

The transaction is expected to be structured on a tax efficient basis, and otherwise in accordance with the requirements of requisite securities laws and the policies of the CSE. Empower has agreed to enter into employment agreements with Yoshi Tyler and Michael Haines, each having an initial term of two years.

Completion of the transaction will be subject to various conditions, including entry into a definitive agreement, completion of due diligence, and receipt of all required shareholder, manager, third party and regulatory approvals, including approval of the CSE. Closing of the transaction is expected to occur prior to October 15, 2020.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative.

ABOUT KAI MEDICAL LABORATORY

Our mission is to change healthcare through science & innovative quality care by providing value added services, accuracy, and consistency. Our unwavering commitment to quality compliance and scientific innovation elevates Kai Medical Laboratory to a new standard in patient care. Kai Medical Laboratory is located in the Dallas Medical District in close proximity to some of the largest healthcare groups in the U.S. including Parkland Hospital, UT Southwestern, Children’s Medical Center, Baylor Scott & White Health (Dallas), Tenet Healthcare (Dallas), CHRISTUS Healthcare (Dallas).

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Dustin Klein

Director
[email protected]
720-352-1398

Investors: Steven McAuley

CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the proposed acquisition of Sun Valley; the proposed transaction terms; the expected number of clinics and patients following the closing; the future potential success of Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Tags: , , , , , , , , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca Announces Acquisition of Medical Diagnostics Laboratory $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Datametrex $DM.ca Reports Record Quarterly Financial Results

Posted by AGORACOM-JC at 7:13 AM on Friday, August 28th, 2020
http://www.smallcapepicenter.com/DM%20square.png
  • From the beginning of June, the Company started to generate revenues from selling of COVID-19 test kits, and its traditional cyber security AI business expanded.
  • This attributed to record quarterly revenue of $1.9M with a greatly improved cash position.
  • Company’s revenue increased by 419% in Q2 compared to the same period of last year.
  • Company’s cash position improved significantly, $577,998 compared to $119,675 at the end of 2019.

TORONTO, Aug. 27, 2020 — Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce record second quarter 2020 (“Q2”) financial and operating results. All currency is in Canadian dollars, unless otherwise stated. All results are reported on a 100% basis.

From the beginning of June, the Company started to generate revenues from selling of COVID-19 test kits, and its traditional cyber security AI business expanded. This attributed to record quarterly revenue of $1.9M with a greatly improved cash position.

The company’s revenue increased by 419% in Q2 compared to the same period of last year. The Company’s cash position improved significantly, $577,998 compared to $119,675 at the end of 2019. The net loss improved with a decrease by 17% ($868,478) compared ($1,011,962) to the same period of last year. There was a $573,250 option issuance expense and $185,078 Depreciation and Amortization expense, which are non-cash based expenses.

Excluding these expenses, the Company was close to break-even. This is reflected in adjusted EBITDA. The Adjusted EBITDA showed a significant improvement. decreasing by 775%, ($96,126) compared to ($841,500) in the same period of last year. 

“In Q2 2020, the Company achieved multiple key milestones, a significant increase in gross revenue and improvement in its cash position. This positive outcome was a direct result of our quick response in implementing a plan to begin selling test kits as result of the global impact of the COVID-19 virus. This resulted in a substantial improvement to the bottom line,” says Marshall Gunter, CEO of the Company.

Outlook

The Company has a number of potential contracts that it is pursuing and anticipates it will have answers on in Q3. Datametrex is in final stages of a COVID-19 test kit supply agreement with a U.S. Government agency. Under the terms of the agreement, the Company will supply 120,000 1copy™ COVID-19 qPCR Multi kit every two weeks for six months.

Datametrex is in final stages of a COVID-19 testing supply agreement to test all landed passenger and crew from cruise ships making a port of call for the Caribbean country of Antigua using the 1copy™ COVID-19 qPCR Multi kit. Under the terms of the agreement, the Company will supply around 6,000 test kits per day and will also supply the latest Polymerase Chain Reaction (PCR) machine (qTOWER3 PCR) to reduce inspection time and lead time. Before landing at the cruise terminal, the cruise line will distribute alphanumeric labels to each passenger and present labels to technicians along with boarding passes and passports at the COVID-19 testing and temperature testing station set up in a passageway exiting the ship.

Datametrex is also in different stages of negotiation on supply agreements for both COVID-19 test kits along with suppling the latest PCR machines (qTOWER3 PCR) with other countries worldwide for mining, education institutions, health agencies, film and TV productions and cruise industry.

Highlights for Q2 2020

  • Recognized revenue of $2.7 million for the six-month 2020 period compared to $875 thousand in same period 2019, of which $1.9 million was earned in the second quarter.
  • The Company started securing and delivering purchase orders of COVID-19 test kits and generated $1.4 million COVID-19 related revenue in Q2 2020 compared to $0 in Q2 2019.
  • The Company has received $1.8 million from the exercise of share purchase warrants and options.
  • The Company introduced Nexalogy’s Social Media Automated Reporting Technologies.
  • The Company completed the second phase of a multi-phase R&D program through the Department of National Defence’s Innovation for Defence Excellence and Security IDEaS program.

Financial Highlights

The following table summarizes revenue, net loss and EBITDA* and Adjusted EBITDA* for the three and six months ended June 30, 2020 and 2019.

 Three months
ended June 30,		   Six months
ended June 30,		  
 2020  2019  % 2020  2019  %
 $ $   $ $   
 Revenue   1,954,394  376,518  419%    2,763,796  875,083  216%
 Net loss    (868,478) (1,011,962) 17%   (1,590,239) (1,916,754) 21%
 EBITDA*    (669,376) (830,227) 24%   (1,197,679) (1,553,756) 30%
 EBITDA per share*        (0.003) (0.004) 73%         (0.005) (0.007) 71%
 Adjusted EBITDA*      (96,126) (841,500) 775%      (353,429) (1,553,756) 340%
 Adjusted EBITDA per share*      (0.0004) (0.004) 10%         (0.001) (0.007) 21%

* Note: EBITDA ( non- IFRS measures) is calculated as Net Loss adjusted for 1. Income taxes, 2. Depreciation and amortization, and 3. Interest and accretion. Adjusted EBITDA (non-IFRS measures) is calculated as EBITFA adjusted for share based compensation.

Non-IFRS financial measures do not have standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Specific items may only be relevant in certain periods. For reconciliation of non-IFRS financial measures please refer to the Company’s Management Discussion and Analysis for the six months ended June 30, 2020.

The Company’s Financial Statements and Management Discussion & Analysis (“MD&A”) are at SEDAR at www.sedar.com.

About Datametrex

Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational Health and Safety goals with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain.

Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Tags: , , , , , , ,
Posted in Datametrex AI Limited | Comments Off on Datametrex $DM.ca Reports Record Quarterly Financial Results

Else Nutrition $BABY.ca Commences First phase of Full-Scale Marketing Campaign for Launch of New Toddler Nutrition Product $KMB $BMY $ABT $WYE

Posted by AGORACOM-JC at 7:16 AM on Thursday, August 27th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • Announced the launch of it’s first phase of the marketing campaign behind the North American Launch of its Plant-based Complete Nutrition product for Toddlers
  • Else has engaged with nearly 50 key influencers (covering social channels: Instagram, Facebook, and blogs), with a combined social media following of over 3.5 million followers / fans
  • The influencers have been handpicked for their enthusiastic following in the mommy/parenting, vegan, healthy-eating, and baby food communities
  • Company has recently signed Ms. Hilaria Baldwin (@hilariabladwin) to a 6-month branded content partnership, which includes high profile media appearances

VANCOUVER, BC / August 27, 2020 / ELSE NUTRITION HOLDINGS INC. (TSXV:BABY)(OTCQX:BABYF)(FSE:0YL) (“Else” or the “Company“), a developer of plant-based alternatives to dairy-based baby nutrition, is pleased to announce the launch of it’s first phase of the marketing campaign behind the North American Launch of its Plant-based Complete Nutrition product for Toddlers.

Else has engaged with nearly 50 key influencers (covering social channels: Instagram, Facebook, and blogs), with a combined social media following of over 3.5 million followers / fans. The influencers have been handpicked for their enthusiastic following in the mommy/parenting, vegan, healthy-eating, and baby food communities. The influencers will engage with their respective audience by posting branded partner content videos and photography of their children using Else Toddler Nutrition throughout the duration of the influencer campaign. Additionally, the Company has recently signed Ms. Hilaria Baldwin (@hilariabladwin) to a 6-month branded content partnership, which includes high profile media appearances.

Furthermore, Else has partnered with 2 significant online communities, to further amplify awareness and reach to encourage trial size orders of its new, Plant-based Complete Nutrition for Toddlers. The Company has partnered with mindbodygreen (MBG), the leading U.S. health and wellness community, which has an aggregate audience of over 27 million people. Else will be featured on paid podcast spots, as well as on MBG’s website and newsletter, as a branded partner throughout September. Else Nutrition is also ramping up sampling efforts of the Toddler Nutrition product to over 6,000 moms in key cities across the U.S., via a partnership with the Moms Meet network of mothers.

In addition to the influencers and online community engagement Else has signed Dr. Jennifer Trachtenberg M.D. “Dr. Jen” as she is known to her patients, is a Board Certified Pediatrician, nationally-renowned parenting expert, author, and mother of 3. She is also Assistant Clinical Professor of Pediatrics at Thelcahn School of Medicine at Mount Sinai, and is hailed as “Dr. Mom” by Dr. Mehmet Oz. Dr. Trachtenberg will create branded partner content for Else for distribution on digital platforms, and will provide professional consultation services spanning consumer and medical marketing. She is a regular contributor on child development and nutrition issues to Parents Magazine, the New York Times, and Today.com.

“I’m excited to be partnering with Else Nutrition. It’s a revolutionary change in toddler formula, or as I like to call it – non-dairy milk alternative for kids – that’s a smart, healthy choice and that tastes good too! The word needs to be spread to moms, dads, pediatricians, nutritionists about this new option for kids’ growth and development,” said Dr. Trachtenberg.

Else Nutrition’s Plant-Based Complete Nutrition for Toddlers & Babies (12+ mo.) is now available for sale on Else’s e-store at elsenutrition.com, and will soon be available on Amazon.com. Consumers can order single 22 oz cans and 4-packs.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

For more information, contact:

Ms. Hamutal Yitzhak, CEO, Co-Founder & Director
ELSE Nutrition Holdings Inc.
E: [email protected]
P: +972(0)3-6445095

Mr. Sokhie Puar, Director of Else Nutrition
Email: [email protected]
Telephone: 604-603-7787

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: Else Nutrition Holdings

Tags: , , , , , , , ,
Posted in All Recent Posts, Else Nutrition Holdings Inc., Featured | Comments Off on Else Nutrition $BABY.ca Commences First phase of Full-Scale Marketing Campaign for Launch of New Toddler Nutrition Product $KMB $BMY $ABT $WYE

Datametrex $DM.ca Starts Selling #COVID19 Test Kits to the Canadian Film Industry With First Contract

Posted by AGORACOM-JC at 12:34 PM on Wednesday, August 26th, 2020
  • Company expands its AI technologies and COVID-19 screening solutions by expanding into the Film and Television Industry in Vancouver, British Columbia
  • ompany also signed the first contract with a Vancouver based production company, Bob Industries LLC, to provide COVID-19 test kits and completed its first COVID-19 testing for the production company
  • With these potential partnerships and the launch of the new COVID-19 pre-screening and screening tools, Datametrex enters the film and television industry

TORONTO, Aug. 26, 2020 — Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) expands its AI technologies and COVID-19 screening solutions by expanding into the Film and Television Industry in Vancouver, British Columbia.

The Company also signed the first contract with a Vancouver based production company, Bob Industries LLC, to provide COVID-19 test kits and completed its first COVID-19 testing for the production company. With these potential partnerships and the launch of the new COVID-19 pre-screening and screening tools, Datametrex enters the film and television industry.

Vancouver is the third largest production centre in North America, worth CDN $3.2 Billion during 2018/19, according to Creative BC. British Columbia is home to several world-class Film and TV studios, includingBridge Studios, Mammoth Studios, Vancouver Film Studios, North Shore Studios, Ironwood Studios, Canadian Motion Picture Park, and The Crossing Studios.

These facilities produce, on average, approximately 65+ movies and 55+ TV series annually, as well as hundreds of other filming days for commercials, TV pilots and other features. This industry generates over 42,000 direct and indirect jobs in Film and TV production, with more than 80 percent located in Metro Vancouver. British Columbia is world-renowned as a versatile and dependable hub for motion picture production.

Total film and TV production in Canada represent $8.92 Billion in production volume and full-time equivalent jobs represent 179,000 workers. When production was shut down in March 2020, Vancouver and area had 46 productions filming and that does not include the TV commercial market. Each of the productions would have a minimum of 100-person film crew.

As the current pandemic continues to impact our world, and with health risks in the film industry, Datametrex is contributing to the health and safety of film organizations. An article that CNBC posted on August 22, 2020, mentions that Solstice Studios is moving a feature film production to Canada, even though it was supposed to film in the U.S., because of available coronavirus testing, making Canada an attractive location for filming.1

This shows that Canada can be an advocate for the Film industry, as we have testing and labs already set up throughout. Additionally, Canada has far fewer instances of coronavirus. The country reported an average of less than 400 new coronavirus cases per day over the past week, compared with more than 46,400 in the U.S., according to data compiled by Johns Hopkins University.

“With the changing nature of the pandemic and worldwide regulations, it is essential that the solutions we develop at Datametrex are flexible and accurate,” said Marshall Gunter, CEO of Datametrex. “With our pre-screening and screening tools, this industry can resume and provide us with the much needed entertainment that this newly indoor, online-based culture requires.”

These tools were developed as a direct response to customer needs and the ever-changing physical distancing recommendations, safety guidelines, and workplace flexibility initiatives being observed across North America and around the globe. Datametrex anticipates that it will have little or no upfront costs associated with importing and selling these test kits.

About Datametrex
Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Email:  [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the time such forward-looking information is made. Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Tags: , , , , , , , ,
Posted in All Recent Posts, Datametrex AI Limited, Featured | Comments Off on Datametrex $DM.ca Starts Selling #COVID19 Test Kits to the Canadian Film Industry With First Contract

Apple $AAPL plans augmented reality #AR content to boost #TV+ video service SPONSOR: Imagine AR $IP.ca $IPNFF $SEV.ca $VST.ca $YDX.ca $NTAR.ca

Posted by AGORACOM-JC at 11:04 AM on Wednesday, August 26th, 2020

SPONSOR: Imagine AR Inc. (IP:CSE) (IPNFF:OTCQB) is an Augmented Reality platform that allows businesses to easily launch AR campaigns. Clients Include: NBA Sacramento Kings, Mall of America, AT&T Shape and The Basketball Hall of Fame. The company recently announced partnership with Engaged Nation, an award winning leader in digital engagement marketing for casinos in addition to a collaboration with Music Superstar Flo Rida Learn More.

http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

Apple plans augmented reality content to boost TV+ video service

  • Apple Inc. is planning to add augmented reality content to its Apple TV+ streaming video service, seeking new ways to attract and retain subscribers and drive interest in AR technology
  • In the new feature, elements of a TV show, like characters or objects, would be displayed on a viewer’s phone or tablet and integrated into the surrounding environment

By: Mark Gurman, Bloomberg News

For example, someone watching a moon-walking scene in the Apple show “For All Mankind” might be able to see a virtual lunar rover on their device’s display, seemingly perched atop their living room coffee table. The option would serve as bonus content akin to the director commentary or trailer that accompany a movie download and would be accessed from Apple’s TV app on the iPhone or iPad.

The AR feature is expected to debut next year, ahead of an Apple headset in 2022 that will be built around augmented and virtual reality, said the people, who asked not to be identified because they weren’t authorized to discuss the plan publicly. A release of the TV+ feature had previously been set for later this year, but the effects of the coronavirus pandemic on software development and film production impeded that goal. Apple could ultimately decide to scrap the plan, the people said. An Apple spokesman declined to comment.

Bonus content has been one of several ways that Apple has been seeking to make TV+ more valuable and keep people subscribed. Apple is preparing to introduce podcasts related to existing TV+ shows, Bloomberg has reported. The company is also developing a series of subscription bundles dubbed Apple One, which would include TV+ along with discounted access to other services like Apple Music and Apple Arcade mobile games. Last week, Apple debuted the first TV+ video bundle, offering customers who subscribe to the Apple service a discounted rate on a package of CBS All Access and Showtime.

The Cupertino, California-based company launched TV+ last year for $4.99 a month, but many customers are still on a free year of service that comes with the purchase of an Apple product. The first trial accounts will expire just weeks after the next iPhones are set to debut in October. The company is considering keeping a free access offer to lure new subscribers but with a reduced period of time, the people said.

While increasing subscription revenue is a key strategy for Apple now, AR is central to the company’s future devices. Some of the upcoming iPhones will include the Lidar 3-D scanners used in the latest iPad Pro, making AR apps quicker to load and giving them a better sense of their environment, people familiar with the products have said.

Read more: Apple’s Secretive Headset Plans Altered by Internal Differences

For 2022, Apple is preparing to launch a headset that mixes augmented and virtual reality with a focus on gaming, video consumption and virtual meetings, Bloomberg has reported. An AR-only pair of glasses is planned for as early as 2023. The AR feature for TV+ would give Apple more content to show off on the future products when they debut. Currently, Apple’s only consumer AR features on the iPhone are the Measure app and Animojis. The company otherwise relies on third-party developers to provide AR tools.

Source: https://www.bnnbloomberg.ca/apple-plans-augmented-reality-content-to-boost-tv-video-service-1.1485053

Tags: , , , , , , , ,
Posted in All Recent Posts, Featured, Imagine AR | Comments Off on Apple $AAPL plans augmented reality #AR content to boost #TV+ video service SPONSOR: Imagine AR $IP.ca $IPNFF $SEV.ca $VST.ca $YDX.ca $NTAR.ca

Thor Gold Riverbed – St. George Icelandic Gold Exploration Update $SX $SX.ca $SXOOF

Posted by AGORACOM at 11:23 AM on Monday, August 24th, 2020

St-Georges Eco-Mining Corp. (CSE:SX) (CNSX:SX.CN) (OTC:SXOOF) (FSE:85G1)is pleased to release the initial fire assays results from the preliminary surface exploration campaign conducted on the Thor Gold Project in order to prepare this summer’s shallow drilling campaign.

The Company’s exploration team collected grab samples from the dry riverbed on both sides of the river running to the west of the historical work areas (See Fig 1.) A total of eight samples were cut from the outcrops.

Figure 1. Project historical work locations and current targeted area in Red.

All grab samples have shown the presence of gold with assays results ranging from 0.001 g/t to 37.4 g/t.

The grab samples collected from the outcrop are, by nature, selected samples and are not necessarily representative of the mineralization hosted on the property.

Three of the grab samples located between 50 and 150 meters of the historical workings are deemed significant enough to warrant some adjustment to the previously planned shallow drilling grid for this summer’s campaign. These grab samples yielded the following results (Table 1):

 Silver g/tCopper %Gold g/tLead
Sample 0035.9 g/t0.015%11.75 g/tNot significant
Sample 0070.6 g/t0.014%2.47 g/tNot significant
Sample 00869.3 g/t0.216%37.4 g/t4.37%

Table 1. Fire Assays Results

Quality Control

Samples were collected and bagged by the SX geological team and transported in secure bags directly from the site to Iceland Resources’ secured warehouse facilities in Keflavik. From there, two Q/C blank samples were added to the other eight samples, and the batch traveled by plane to ALS Global Laboratories (ISO/IEC 17025 accredited) in Loughrea, Ireland. All samples were tested using four acid trace analysis (ME-ICP61). Samples that yielded precious metals content in excess of 10 ppm were analyzed a second time via gravity separation and fire assay finish.

About Thor Gold

The Thormodsdalur Gold Project is located about 20km east of the city center of Reykjavik and south-east of Lake Hafravatn. The project was discovered in 1908. The property produced a gold concentrate from 1911 to 1925, which was shipped to Germany for processing. Over 300 meters of tunnels explored and mined one or more quartz veins and wall rock below open cuts at the surface.

Studies between 1996 and 2013 identified the project mineralization as a low sulfidation system hosted by basic to intermediate flows of Pliocene to Miocene age. The host contains banded chalcedony and ginguro within a fault zone up to five meters in width. To date, the identified gold trend has a known strike length of 700 meters determined by drill intercepts. Petrographic analysis of the vein material identified gold occurring in its free form and as part of an assemblage with pyrite and chalcopyrite. Petrographic and XRD studies show an evolution of the vein system from the zeolite assemblage to quartz-adularia and, lastly, to minor calcite.

Thirty-two holes have been drilled within the license area, for a total of 2439 meters. Gold values vary from less than 0.5 g/t to a maximum of 415 g/t. (These values were obtained from selected random intervals and cannot be construed to be representative of any particular thickness or overall length.) The best intercepts from the diamond drilling are 33.5m of 8.0 g/t Au (true thickness) and 5.2m of 35.4 g/t Au (true thickness).

Gary McLearn, A professional geoscientist (Ontario APGO #2900) and an Independent Qualified Person as defined by National Instrument 43-101, has prepared and supervised the preparation and has approved the scientific and technical disclosure in the news release.

Mr. Herb Duerr, P. Geo. (AIPG, CPG #11498), a St-Georges’ director, has also reviewed the scientific and technical content of this release. Mr. Duerr is a qualified person as defined by National Instrument 43-101 Standards of Disclosure for Mineral Projects.

ON BEHALF OF THE BOARD OF DIRECTORS

“Vilhjalmur Thor Vilhjalmsson”

Vilhjalmur Thor Vilhjalmsson

President and CEO

About St-Georges

St-Georges is developing new technologies to solve some of the most common environmental problems in the mining industry.

The Company controls directly or indirectly, through rights of first refusal, all of the active mineral tenures in Iceland. It also explores for nickel on the Julie Nickel Project & for industrial minerals on Quebec’s North Shore and for lithium and rare metals in Northern Quebec and in the Abitibi region. Headquartered in Montreal, St-Georges’ stock is listed on the CSE under the symbol SX, on the US OTC under the Symbol SXOOF and on the Frankfurt Stock Exchange under the symbol 85G1

Tags: , , , , , , , , ,
Posted in All Recent Posts, St Georges Eco-Mining Technologies | Comments Off on Thor Gold Riverbed – St. George Icelandic Gold Exploration Update $SX $SX.ca $SXOOF

Hollister Biosciences Inc. $HOLL.ca Reports Second Quarter 2020 Results With $8.47 Million In Revenue $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:25 AM on Monday, August 24th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1

Multi-state operator and diversified cannabis branding company generates record quarterly revenue and delivers profitable second quarter

  • Revenue generated for the three-month period ended June 30th, 2020 was $8.47 million versus $0.2 million from the second quarter last year, representing significant year over year revenue growth
  • Revenue was primarily generated from the sale of concentrates, pre-rolls and contract manufacturing services

VANCOUVER, BC, Aug. 24, 2020 – Hollister Biosciences Inc. (CSE: HOLL), (OTC: HSTRF), (FRANKFURT: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 230 dispensaries throughout California, and over 80 dispensaries throughout Arizona, announces financial results for the second quarter 2020 (ended June 30th, 2020).  All figures in US Dollars unless otherwise stated.

Second Quarter Financial Highlights

  • Revenue generated for the three-month period ended June 30th, 2020 was $8.47 million versus $0.2 million from the second quarter last year, representing significant year over year revenue growth
  • Revenue was primarily generated from the sale of concentrates, pre-rolls and contract manufacturing services
  • Net income for the three-month period ended June 30th, 2020 was $0.3 million compared to a net loss of $2.1 million in the first quarter of 2020

“Our second quarter results are encouraging and in line with our objective to increase revenue and profitability” shared Alex Somjen, President of Hollister Biosciences Inc.  “These financial results are a product of increased brand awareness, strategic M&A and strategic partnerships put in place over the previous six months.”

Operational Highlights and Strategic Objectives for 2020

  • The challenges presented by the COVID-19 pandemic have accelerated Hollister’s plans to roll out direct to consumer delivery
    • The brand will be called “Dreamy Delivery” and the first delivery hub is expected to launch in the fourth quarter of 2020 with statewide delivery anticipated by the end of 2021
  • Design and build-out of Hollister’s 100% owned subsidiary, Venom Extracts, in the Company’s Hollister, CA facility are underway
  • Product development and product launch associated with the Company’s joint venture with Tactical Relief and the Company’s 100% owned subsidiary, Alpha Mind Brands Inc., respectively, are progressing
  • The Company’s partnership with Tommy Chong’s Cannabis is progressing well, with Tommy Chong’s Full Spectrum Elixir now being distributed in 20 dispensaries throughout the state of California by Hollister’s distribution partner Indus Holdings Inc. (CSE: INDS)

“Enormously proud of our teams in Arizona & California.  Our staff continues to overcome obstacles like the global pandemic while posting record revenue numbers. We look forward to continuing to execute on our plans while increasing value for our shareholders.” Said Carl Saling CEO of Hollister Biosciences.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website:www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com 

View original content to download multimedia:http://www.prnewswire.com/news-releases/hollister-biosciences-inc-reports-second-quarter-2020-results-301116831.html

SOURCE Hollister Biosciences Inc.

Tags: , , , , , , , , ,
Posted in All Recent Posts, Featured, Hollister Biosciences | Comments Off on Hollister Biosciences Inc. $HOLL.ca Reports Second Quarter 2020 Results With $8.47 Million In Revenue $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

University of Pittsburgh Joseph M. Katz Graduate School of Business Selects ImagineAR $IP.ca $IPNFF as Partner in New MBA Course $SEV.ca $VST.ca $YDX.ca $NTAR.ca

Posted by AGORACOM-JC at 7:19 AM on Monday, August 24th, 2020
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg
  • Announced the Joseph M. Katz Graduate School of Business at the University of Pittsburgh is unveiling a new and exciting business disruption series course called, “Augmented and Virtual Reality (AR/VR) for Brands and Strategy.”
  • The course, in partnership with ImagineAR will be taught by Vanitha Swaminathan, Thomas Marshall Professor of Marketing. “Augmented and Virtual Reality for Brands and Strategy” will be initially available for MBA and MS students and eventually to undergraduate students at the College of Business Administration

VANCOUVER, BC and ERIE, PA, Aug. 24, 2020 – ImagineAR (CSE: IP) (OTCQB: IPNFF) an Augmented Reality Company that enables sports teams, retailers and brands to create their own instant mobile phone AR campaigns,  is pleased to announce the Joseph M. Katz Graduate School of Business at the University of Pittsburgh is unveiling a new and exciting business disruption series course called, “Augmented and Virtual Reality (AR/VR) for Brands and Strategy.”

The course, in partnership with ImagineAR will be taught by Vanitha Swaminathan, Thomas Marshall Professor of Marketing. “Augmented and Virtual Reality for Brands and Strategy” will be initially available for MBA and MS students and eventually to undergraduate students at the College of Business Administration. The entirety of the course will be taught in an online format.  U.S. News & World Report has ranked the Katz Graduate School of Business 39th in its 2021 ranking of the Best Business Schools in the United States.

During the span of the course, students will work in teams to identify how to apply augmented and virtual reality to a real business or company and to design a branding campaign. To conclude the course, students will present a 10-minute video showcasing their ideas.

“We’re thrilled to introduce the new series of business disruption courses,” said Sara Moeller, Associate Dean for Graduate Programs. “Augmented and Virtual Reality for Brands and Strategy, the inaugural course, is the first step in many new and exciting game-changing courses to come.”

AR/VR technologies have the potential to have a transformational role in how students learn, how managers make decisions and how consumers interact with products and branded experiences. Every business today is required to have an augmented reality strategy in order to unlock creative potential inherent in various touchpoints and user interfaces. 

“The offering of this course is extremely unique and timely,” said Swaminathan. “The current health crisis has required marketers to be even more creative in how to engage fans and customers. Augmented and virtual reality tools will provide new, creative ways of engaging with customers during this challenging period of social distancing.”

Alen Paul Silverrstieen, CEO & President of Imagine AR stated, “The adoption of the AR/VR course by the esteemed Joseph M. Katz Graduate School of Business is a real testament to ImagineAR.  The school has identified ImagineAR as an industry leader and AR as an enormous opportunity for brands to engage customers during these times where traditional methods would not suffice. I look forward to working with Professor Swaminathan on this revolutionary course work.”

The course will tie into a new case competition, Katz Augmented Reality Case Competition (ARCC), co-sponsored by the Center for Branding, Katz Marketing Club, Katz Technology Club, and ImagineAR. Katz graduate students will compete in teams of four to showcase their futuristic and creative ideas for how products and brands can become more innovative in the future. The Katz ARCC will provide an important way for students to gain exposure to AR/VR technologies and will challenge them to think through the various ways in which it can improve the brand experience.

To learn more about the Augmented and Virtual Reality for Brands and Strategy course, click this link.

About ImagineAR

ImagineAR Inc. (CSE: IP) (OTC: IPNFF) is an augmented reality (AR) platform, ImagineAR.com, that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage videos, information, advertisements, coupons, 3D holograms and any interactive content all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The AR Enterprise platform supports both IOS and Android mobile devices and upcoming wearable technologies.

All trademarks of the property of respective owners.

ON BEHALF OF THE BOARD

Alen Paul Silverrstieen
President & CEO
(818) 850-2490
https://twitter.com/IPtechAR
https://www.facebook.com/imaginationparktechnologies
https://www.instagram.com/iptechar
https://www.linkedin.com/company/imagination-park-technologies-inc

We encourage you to do your own due diligence and ask your broker if ImagineAR Inc. (cse: IP) is suitable for your particular investment portfolio*.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward looking information is based on certain key expectations and assumptions made by ImagineAR Inc. management. Although ImagineAR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because ImagineAR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and ImagineAR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. 

SOURCE ImagineAR

Tags: , , , , , , ,
Posted in Imagine AR | Comments Off on University of Pittsburgh Joseph M. Katz Graduate School of Business Selects ImagineAR $IP.ca $IPNFF as Partner in New MBA Course $SEV.ca $VST.ca $YDX.ca $NTAR.ca

« Older Entries
Newer Entries »